Search results
Results from the WOW.Com Content Network
Apixaban is recommended by the National Institute for Health and Clinical Excellence for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation and at least one of the following risk factors: prior stroke or transient ischemic attack, age 75 years or older, diabetes, or symptomatic heart failure.
Cyclobenzaprine, sold under several brand names including, historically, Flexeril, is a muscle relaxer used for muscle spasms from musculoskeletal conditions of sudden onset. [5] It is not useful in cerebral palsy. [5] It is taken by mouth. [5] Common side effects include headache, feeling tired, dizziness, and dry mouth. [5]
Side effects may include bleeding, most commonly from the nose, gastrointestinal tract (GI) or genitourinary system. [2] Compared to the risk of bleeding with warfarin use, direct factor Xa inhibitors have a higher risk of GI bleeding, but lower risk of bleeding in the brain . [ 2 ]
Medicare launches drug price negotiations. Other nations typically pay far less for medications, in large part because their governments often determine the cost. However, that gap could begin to ...
Other drugs on the list include AstraZeneca’s diabetes and heart failure treatment Farxiga and three drugs from Johnson & Johnson: the blood thinner Xarelto, the blood cancer treatment Imbruvica ...
Many of these cases have lead to class action lawsuits and proceedings by the Federal Trade Commision (FTC), resulting in a number of settlements worth millions — or even billions — of dollars ...
Despite being anticholinergic, it does not have the systemic anticholinergic side effects seen in other such drugs. [ 4 ] Peppermint oil has been traditionally used as an antispasmodic, and a review of studies on the topic found that it "could be efficacious for symptom relief in IBS " [ 5 ] (as an antispasmodic) although more carefully ...
The Food and Drug Administration has granted approval for the next-generation anticlotting medication Eliquis, the regulator announced in a news release. The drug, administered in the form of a ...